

# 04 / 経営成績 Financial Statements

## 財務ハイライト // Financial Summary

日本基準 (J-GAAP)

	'04/3	'05/3	'06/3	'07/3	'08/3	'09/3	'10/3
売上収益*1	¥1,158,402	¥1,296,315	¥1,556,606	¥1,790,026	¥1,896,539	¥1,788,223	¥1,620,915
コア営業利益	—	—	—	—	—	—	—
営業利益 <sup>注1</sup>	66,620	105,182	120,790	139,623	102,397	2,114	51,455
経常利益 (損失)	66,328	123,476	141,127	157,981	92,790	(32,624)	34,957
親会社の所有者に帰属する当期利益 (損失)*2	34,318	64,452	90,665	93,860	63,083	(59,164)	14,723
資産合計*3	1,549,291	1,648,796	2,178,377	2,324,906	2,358,929	2,022,553	2,383,906
親会社の所有者に帰属する持分合計*4	506,122	569,601	719,760	792,538	768,110	544,366	575,368
資本合計*5 <sup>注2</sup>	606,154	676,869	944,224	1,030,521	1,006,046	775,628	821,436
営業活動によるキャッシュ・フロー	97,052	159,819	122,783	142,917	156,578	78,428	132,872
投資活動によるキャッシュ・フロー	(103,240)	(117,953)	(180,679)	(164,239)	(182,679)	(206,237)	(269,402)
フリー・キャッシュ・フロー	(6,188)	41,866	(57,896)	(21,322)	(26,101)	(127,809)	(136,530)
財務活動によるキャッシュ・フロー	(9,315)	(31,204)	70,581	35,558	7,090	112,539	168,709
設備投資額 (十億円)	110.2	125.8	124.9	159.8	142.5	134.1	103.2
減価償却費 (十億円)	82.5	88.2	104.9	113.9	125.0	140.7	116.1
研究開発費 (十億円)	75.2	78.2	91.9	97.7	105.4	131.1	117.3
売上収益コア営業利益率 (%) <sup>*6</sup>	5.8	8.1	7.8	7.8	5.4	0.1	3.2
売上収益当期利益率 (%) <sup>*7</sup>	3.0	5.0	5.8	5.2	3.3	(3.3)	0.9
売上収益研究開発費比率 (%) <sup>*8</sup>	6.5	6.0	5.9	5.5	5.6	7.3	7.2
有利子負債 (十億円)	485.3	470.7	578.6	641.0	673.9	795.4	997.9
D/Eレシオ (倍)	0.8	0.7	0.6	0.6	0.7	1.0	1.2
親会社所有者帰属持分比率 (%) <sup>*9</sup>	32.7	34.5	33.0	34.1	32.6	26.9	24.1
キャッシュ・フロー対有利子負債比率	5.0	2.9	4.7	4.5	4.3	10.1	7.5
インタレスト・カバレッジ・レシオ (倍)	12.3	22.4	15.9	13.3	13.2	6.5	11.0
金融収支 (十億円)	(2.8)	(3.0)	(2.2)	(3.9)	(2.8)	(2.7)	(5.0)
ROE (%)	7.2	12.0	14.1	12.4	8.1	(9.0)	2.6
ROA (%)	2.3	4.0	4.7	4.2	2.7	(2.7)	0.7
基本的1株当たり当期利益 (円) <sup>*10</sup>	20.72	38.94	54.80	56.82	38.20	(35.84)	8.92
1株当たり親会社所有者帰属持分 (円) <sup>*11</sup>	306.05	344.58	435.51	479.87	465.21	329.74	348.52
1株当たり配当金 (円)	6.00	8.00	10.00	12.00	12.00	9.00	6.00
配当性向 (%)	28.9	20.5	18.2	21.1	31.4	—	67.3
PER (倍)	23.6	13.6	17.5	15.7	16.7	(9.3)	51.2
PBR (倍)	1.6	1.5	2.2	1.9	1.4	1.0	1.3
従業員数 (人)	19,036	20,195	24,160	24,691	25,588	26,902	27,828
研究開発人員 (人)	2,660	2,628	3,100	3,148	3,392	3,511	3,764
連結子会社数 (社)	110	104	105	105	116	126	143
為替 (円/\$)	113.19	107.55	113.32	116.97	114.44	100.71	92.89
ナフサ価格 (円/KL)	25,600	32,200	42,400	50,000	61,500	58,900	41,200
海外売上収益の地域別内訳 (十億円) <sup>*12</sup>							
アジア	239.9	346.4	444.0	543.3	591.7	550.5	539.5
北米	44.9	44.3	53.8	46.1	46.1	46.1	75.0
欧州	50.4	56.9	58.7	72.0	67.6	80.4	71.8
中東・アフリカ	6.2	10.0	15.8	43.0	44.1	37.3	21.8
中南米	7.2	9.2	12.7	14.9	17.1	18.2	12.3
オセアニア他	15.5	19.4	26.0	28.5	22.2	17.3	8.5
合計	364.1	486.2	611.0	747.8	788.8	749.8	728.9
海外売上収益比率 (%) <sup>*13</sup>	31.4	37.5	39.2	41.8	41.6	41.9	45.0

日本基準での勘定科目は以下の通り。

\*1 売上高、\*2 親会社株主に帰属する当期純利益 (損失)、\*3 総資産、\*4 自己資本、\*5 純資産、\*6 売上高営業利益率 (%)、\*7 売上高当期純利益率 (%)、\*8 売上高研究開発費比率 (%)、\*9 自己資本比率 (%)、\*10 1株当たり当期純利益 (損失) (円)、\*11 1株当たり純資産 (円)、\*12 海外売上高の地域別内訳 (十億円)、\*13 海外売上高比率 (%)

(注) 1 2016年3月期までは日本基準の営業利益、2017年3月期以降はIFRSの営業利益を掲載。

2 2007年3月期の会計基準変更に伴い、2004年3月期から2006年3月期までは資本合計に少数株主持分を加えた数値を掲載。

## 国際会計基準 (IFRS)

(百万円)

	'11/3	'12/3	'13/3	'14/3	'15/3	'16/3	'17/3	'18/3	'19/3	(監査中) '20/3
	¥1,982,435	¥1,947,884	¥1,952,492	¥2,243,794	¥2,376,697	¥2,101,764	¥1,939,069	¥2,190,509	¥2,318,572	¥2,225,804
	—	—	—	—	—	—	184,547	262,694	204,252	132,652
	87,957	60,688	45,016	100,842	127,346	164,446	126,467	250,923	182,972	137,517
	84,091	50,714	50,252	111,109	157,414	171,217	—	—	—	—
	24,434	5,587	(51,076)	36,977	52,192	81,451	76,540	133,768	117,992	30,926
	2,367,314	2,336,953	2,472,091	2,788,507	2,880,396	2,662,150	2,878,193	3,068,685	3,171,618	3,650,332
	522,473	486,235	496,500	643,297	791,319	766,874	812,612	927,141	998,702	922,342
	758,886	720,901	747,482	934,506	1,118,216	1,090,776	1,115,903	1,252,214	1,351,886	1,388,837
	176,228	124,491	171,595	194,362	260,854	261,172	185,776	293,250	208,143	106,012
	(155,987)	(123,975)	(165,772)	(135,177)	(56,628)	(53,678)	(205,697)	(154,520)	(180,837)	(499,670)
	20,241	516	5,823	59,185	204,226	207,494	(19,921)	138,730	27,306	(393,658)
	17,985	2,054	(36,009)	(59,084)	(151,465)	(177,956)	(523)	(94,264)	(60,866)	373,542
	98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	116.3
	147.0	114.9	115.5	115.7	119.2	116.6	110.3	107.1	112.5	131.7
	138.1	122.3	125.0	141.3	147.9	155.8	158.0	165.3	163.5	174.3
	4.4	3.1	2.3	4.5	5.4	7.8	9.5	12.0	8.8	6.0
	1.2	0.3	(2.6)	1.6	2.2	3.9	3.9	6.1	5.1	1.4
	7.0	6.3	6.4	6.3	6.2	7.4	8.1	7.5	7.1	7.8
	1,040.3	1,053.0	1,060.6	1,074.6	980.2	831.5	884.1	842.2	839.5	1,304.7
	1.4	1.5	1.4	1.1	0.9	0.8	0.8	0.7	0.6	0.9
	22.1	20.8	20.1	23.1	27.5	28.8	28.2	30.2	31.5	25.3
	5.9	8.5	6.2	5.5	3.8	3.2	4.8	2.9	4.0	12.3
	13.7	10.2	13.2	15.0	19.0	22.6	16.4	27.8	19.0	8.3
	(6.3)	(4.7)	(5.4)	(4.9)	0.7	(2.7)	(2.2)	(0.5)	0.2	(1.6)
	4.5	1.1	(10.4)	6.5	7.3	10.5	9.8	15.4	12.3	3.2
	1.0	0.2	(2.1)	1.4	1.8	2.9	2.8	4.5	3.8	0.9
	14.86	3.42	(31.25)	22.62	31.93	49.84	46.81	81.81	72.17	18.91
	319.61	297.45	303.74	393.58	484.17	469.25	496.96	567.04	610.82	564.12
	9.00	9.00	6.00	9.00	9.00	14.00	14.00	22.00	22.00	17.00
	60.6	263.3	—	39.8	28.2	28.1	29.9	26.9	30.5	89.9
	27.9	102.9	(9.4)	16.8	19.4	10.2	13.3	7.6	7.1	17.0
	1.3	1.2	1.0	1.0	1.3	1.1	1.3	1.1	0.8	0.6
	29,382	29,839	30,396	30,745	31,039	31,094	32,536	31,837	32,542	33,586
	3,933	3,989	3,951	3,952	3,913	3,831	4,010	4,034	3,937	4,221
	146	145	162	164	167	160	170	178	184	218
	85.74	79.08	82.91	100.17	109.76	120.15	108.34	110.85	110.92	108.70
	47,500	54,900	57,500	67,300	63,500	42,800	34,700	41,900	49,400	43,000
	744.3	716.3	736.4	883.0	964.0	819.8	741.1	842.6	936.4	880.7
	165.4	159.9	176.3	233.0	257.3	306.2	305.8	366.9	380.4	384.0
	90.5	82.9	78.8	106.7	96.6	82.3	69.1	85.9	95.1	93.1
	33.2	25.7	24.2	29.7	61.9	30.3	22.4	37.4	42.3	46.9
	13.6	14.4	18.8	29.3	36.3	37.9	34.4	39.5	43.1	45.8
	9.7	9.7	9.4	11.2	12.2	12.7	10.7	12.4	8.5	10.2
	1,056.7	1,009.0	1,043.8	1,292.9	1,428.4	1,289.2	1,183.4	1,384.7	1,505.7	1,460.7
	53.3	51.8	53.5	57.6	60.1	61.3	61.0	63.2	64.9	65.6

## 財務ハイライト // Financial Summary

### J-GAAP

	'04/3	'05/3	'06/3	'07/3	'08/3	'09/3	'10/3
Sales revenue*1	1,158,402	1,296,315	1,556,606	¥1,790,026	¥1,896,539	¥1,788,223	¥1,620,915
Core operating income	—	—	—	—	—	—	—
Operating income <sup>Note 1</sup>	66,620	105,182	120,790	139,623	102,397	2,114	51,455
Ordinary income (loss)	66,328	123,476	141,127	157,981	92,790	(32,624)	34,957
Net income (loss) attributable to owners of the parent	34,318	64,452	90,665	93,860	63,083	(59,164)	14,723
Total assets	1,549,291	1,648,796	2,178,377	2,324,906	2,358,929	2,022,553	2,383,906
Equity attributable to owners of the parent*2	506,122	569,601	719,760	792,538	768,110	544,366	575,368
Total equity*3 <sup>Note 2</sup>	606,154	676,869	944,224	1,030,521	1,006,046	775,628	821,436
Cash flows from operating activities	97,052	159,819	122,783	142,917	156,578	78,428	132,872
Cash flows from investing activities	(103,240)	(117,953)	(180,679)	(164,239)	(182,679)	(206,237)	(269,402)
Free cash flow	(6,188)	41,866	(57,896)	(21,322)	(26,101)	(127,809)	(136,530)
Cash flows from financing activities	(9,315)	(31,204)	70,581	35,558	7,090	112,539	168,709
Capital expenditures (billions of yen)	110.2	125.8	124.9	159.8	142.5	134.1	103.2
Depreciation and amortization expenses (billions of yen)	82.5	88.2	104.9	113.9	125.0	140.7	116.1
Research and development expenses (billions of yen)	75.2	78.2	91.9	97.7	105.4	131.1	117.3
Core operating income to sales revenue (%)*4	5.8	8.1	7.8	7.8	5.4	0.1	3.2
Net income to sales revenue (%)*5	3.0	5.0	5.8	5.2	3.3	(3.3)	0.9
Research and development expenses to sales revenue (%)*6	6.5	6.0	5.9	5.5	5.6	7.3	7.2
Interest-bearing liabilities (billions of yen)	485.3	470.7	578.6	641.0	673.9	795.4	997.9
D/E ratio (times)	0.8	0.7	0.6	0.6	0.7	1.0	1.2
Equity attributable to owners of the parent to total assets (%)*7	32.7	34.5	33.0	34.1	32.6	26.9	24.1
Ratio of interest-bearing debt to cash flow	5.0	2.9	4.7	4.5	4.3	10.1	7.5
Interest coverage ratio (times)	12.3	22.4	15.9	13.3	13.2	6.5	11.0
Net interest expenses (billions of yen)	(2.8)	(3.0)	(2.2)	(3.9)	(2.8)	(2.7)	(5.0)
Return on equity (%)	7.2	12.0	14.1	12.4	8.1	(9.0)	2.6
Return on assets (%)	2.3	4.0	4.7	4.2	2.7	(2.7)	0.7
Basic earnings per share (yen)*8	20.72	38.94	54.80	56.82	38.20	(35.84)	8.92
Equity attributable to owners of the parent per share (yen)*9	306.05	344.58	435.51	479.87	465.21	329.74	348.52
Cash dividends per share (yen)	6.00	8.00	10.00	12.00	12.00	9.00	6.00
Dividend payout ratio (%)	28.9	20.5	18.2	21.1	31.4	—	67.3
Price earnings ratio (times)	23.6	13.6	17.5	15.7	16.7	(9.3)	51.2
Price book-value ratio (times)	1.6	1.5	2.2	1.9	1.4	1.0	1.3
Number of employees	19,036	20,195	24,160	24,691	25,588	26,902	27,828
Number of research and development employees	2,660	2,628	3,100	3,148	3,392	3,511	3,764
Number of consolidated subsidiaries	110	104	105	105	116	126	143
Exchange rate (yen/\$)	113.19	107.55	113.32	116.97	114.44	100.71	92.89
Naphtha price (yen/KL)	25,600	32,200	42,400	50,000	61,500	58,900	41,200
Overseas sales revenue by region (billions of yen)*10							
Asia	239.9	346.4	444.0	543.3	591.7	550.5	539.5
North America	44.9	44.3	53.8	46.1	46.1	46.1	75.0
Europe	50.4	56.9	58.7	72.0	67.6	80.4	71.8
Middle East and Africa	6.2	10.0	15.8	43.0	44.1	37.3	21.8
Central and South America	7.2	9.2	12.7	14.9	17.1	18.2	12.3
Oceania and others	15.5	19.4	26.0	28.5	22.2	17.3	8.5
Total	364.1	486.2	611.0	747.8	788.8	749.8	728.9
Overseas sales revenue ratio (%)*11	31.4	37.5	39.2	41.8	41.6	41.9	45.0

Account titles of J-GAAP are as follows:

\*1 Net sales; \*2 Shareholders' equity; \*3 Net assets; \*4 Operating margin (%); \*5 Net income ratio to net sales (%);

\*6 Research and development expenses ratio to net sales (%); \*7 Shareholders' equity ratio (%); \*8 Net income (loss) per share (yen); \*9 Net assets per share (yen);

\*10 Overseas sales by region (billions of yen); \*11 Overseas sales ratio (%)

(Notes) 1. The operating income had been presented under J-GAAP up to FY2015, and under IFRS from FY2016 onward.

2. In line with the change in accounting standards in FY2006, figures from FY2003 to FY2005 were restated; minority stakes were added to the total equity.

						IFRS	(Millions of yen)			
'11/3	'12/3	'13/3	'14/3	'15/3	'16/3	'17/3	'18/3	'19/3	(Unaudited) '20/3	
¥1,982,435	¥1,947,884	¥1,952,492	¥2,243,794	¥2,376,697	¥2,101,764	¥1,939,069	¥2,190,509	¥2,318,572	¥2,225,804	
—	—	—	—	—	—	184,547	262,694	204,252	132,652	
87,957	60,688	45,016	100,842	127,346	164,446	126,467	250,923	182,972	137,517	
84,091	50,714	50,252	111,109	157,414	171,217	—	—	—	—	
24,434	5,587	(51,076)	36,977	52,192	81,451	76,540	133,768	117,992	30,926	
2,367,314	2,336,953	2,472,091	2,788,507	2,880,396	2,662,150	2,878,193	3,068,685	3,171,618	3,650,332	
522,473	486,235	496,500	643,297	791,319	766,874	812,612	927,141	998,702	922,342	
758,886	720,901	747,482	934,506	1,118,216	1,090,776	1,115,903	1,252,214	1,351,886	1,388,837	
176,228	124,491	171,595	194,362	260,854	261,172	185,776	293,250	208,143	106,012	
(155,987)	(123,975)	(165,772)	(135,177)	(56,628)	(53,678)	(205,697)	(154,520)	(180,837)	(499,670)	
20,241	516	5,823	59,185	204,226	207,494	(19,921)	138,730	27,306	(393,658)	
17,985	2,054	(36,009)	(59,084)	(151,465)	(177,956)	(523)	(94,264)	(60,866)	373,542	
98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	116.3	
147.0	114.9	115.5	115.7	119.2	116.6	110.3	107.1	112.5	131.7	
138.1	122.3	125.0	141.3	147.9	155.8	158.0	165.3	163.5	174.3	
4.4	3.1	2.3	4.5	5.4	7.8	9.5	12.0	8.8	6.0	
1.2	0.3	(2.6)	1.6	2.2	3.9	3.9	6.1	5.1	1.4	
7.0	6.3	6.4	6.3	6.2	7.4	8.1	7.5	7.1	7.8	
1,040.3	1,053.0	1,060.6	1,074.6	980.2	831.5	884.1	842.2	839.5	1,304.7	
1.4	1.5	1.4	1.1	0.9	0.8	0.8	0.7	0.6	0.9	
22.1	20.8	20.1	23.1	27.5	28.8	28.2	30.2	31.5	25.3	
5.9	8.5	6.2	5.5	3.8	3.2	4.8	2.9	4.0	12.3	
13.7	10.2	13.2	15.0	19.0	22.6	16.4	27.8	19.0	8.3	
(6.3)	(4.7)	(5.4)	(4.9)	0.7	(2.7)	(2.2)	(0.5)	0.2	(1.6)	
4.5	1.1	(10.4)	6.5	7.3	10.5	9.8	15.4	12.3	3.2	
1.0	0.2	(2.1)	1.4	1.8	2.9	2.8	4.5	3.8	0.9	
14.86	3.42	(31.25)	22.62	31.93	49.84	46.81	81.81	72.17	18.91	
319.61	297.45	303.74	393.58	484.17	469.25	496.96	567.04	610.82	564.12	
9.00	9.00	6.00	9.00	9.00	14.00	14.00	22.00	22.00	17.00	
60.6	263.3	—	39.8	28.2	28.1	29.9	26.9	30.5	89.9	
27.9	102.9	(9.4)	16.8	19.4	10.2	13.3	7.6	7.1	17.0	
1.3	1.2	1.0	1.0	1.3	1.1	1.3	1.1	0.8	0.6	
29,382	29,839	30,396	30,745	31,039	31,094	32,536	31,837	32,542	33,586	
3,933	3,989	3,951	3,952	3,913	3,831	4,010	4,034	3,937	4,221	
146	145	162	164	167	160	170	178	184	218	
85.74	79.08	82.91	100.17	109.76	120.15	108.34	110.85	110.92	108.70	
47,500	54,900	57,500	67,300	63,500	42,800	34,700	41,900	49,400	43,000	
744.3	716.3	736.4	883.0	964.0	819.8	741.1	842.6	936.4	880.7	
165.4	159.9	176.3	233.0	257.3	306.2	305.8	366.9	380.4	384.0	
90.5	82.9	78.8	106.7	96.6	82.3	69.1	85.9	95.1	93.1	
33.2	25.7	24.2	29.7	61.9	30.3	22.4	37.4	42.3	46.9	
13.6	14.4	18.8	29.3	36.3	37.9	34.4	39.5	43.1	45.8	
9.7	9.7	9.4	11.2	12.2	12.7	10.7	12.4	8.5	10.2	
1,056.7	1,009.0	1,043.8	1,292.9	1,428.4	1,289.2	1,183.4	1,384.7	1,505.7	1,460.7	
53.3	51.8	53.5	57.6	60.1	61.3	61.0	63.2	64.9	65.6	

## セグメント情報 // Sector Information

日本基準 (J-GAAP)

			'04/3	'05/3	'06/3	'07/3	'08/3
売上収益 Sales revenue	基礎化学	Basic Chemicals	¥ 199,050	¥ 225,765	¥ 252,399	¥ 314,004	¥ 314,718
	石油化学	Petrochemicals & Plastics	362,411	412,576	486,054	539,065	603,326
日本基準 売上高 J-GAAP Net sales	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	80,594	84,059	79,011	90,882	92,937
	情報電子化学	IT-related Chemicals	123,525	174,792	229,240	266,436	297,515
	健康・農業関連事業	Health & Crop Sciences	167,105	171,644	186,232	198,310	200,378
	医薬品	Pharmaceuticals	166,561	170,707	233,101	234,546	237,592
	その他	Others	59,156	56,772	90,569	146,783	150,073
	合計	Total	1,158,402	1,296,315	1,556,606	1,790,026	1,896,539
コア営業利益 Core operating income	基礎化学	Basic Chemicals	2,580	5,212	9,994	13,483	10,559
	石油化学	Petrochemicals & Plastics	(1,639)	14,992	17,918	23,596	4,518
日本基準 営業利益 (損失) J-GAAP Operating income (loss)	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	8,812	11,545	9,826	13,085	11,430
	情報電子化学	IT-related Chemicals	14,335	18,742	21,704	3,457	6,290
	健康・農業関連事業	Health & Crop Sciences	10,719	14,828	16,578	23,251	20,914
	医薬品	Pharmaceuticals	27,839	34,440	38,286	56,231	46,464
	その他	Others	4,892	5,705	5,762	8,012	3,688
	消去	Elimination	(918)	(282)	(722)	(1,492)	(1,466)
	合計	Total	66,620	105,182	120,790	139,623	102,397
売上収益コア営業利益率 (%) Core operating income to sales revenue (%)	基礎化学	Basic Chemicals	1.30	2.31	3.96	4.29	3.36
	石油化学	Petrochemicals & Plastics	(0.45)	3.63	3.69	4.38	0.75
日本基準 売上高営業利益率 (%) J-GAAP Operating margin (%)	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	10.93	13.73	12.44	14.40	12.30
	情報電子化学	IT-related Chemicals	11.60	10.72	9.47	1.30	2.11
	健康・農業関連事業	Health & Crop Sciences	6.41	8.64	8.90	11.72	10.44
	医薬品	Pharmaceuticals	16.71	20.17	16.42	23.97	19.56
	その他	Others	8.27	10.05	6.36	5.46	2.46
	合計	Total	5.75	8.11	7.76	7.80	5.40
設備投資額 (十億円) Capital expenditures (billions of yen)	基礎化学	Basic Chemicals	13.3	18.2	20.7	24.6	27.6
	石油化学	Petrochemicals & Plastics	11.8	13.7	16.1	16.9	21.2
日本基準	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	7.0	7.5	7.0	4.6	6.9
	情報電子化学	IT-related Chemicals	37.2	40.2	44.0	72.0	33.4
	健康・農業関連事業	Health & Crop Sciences	5.7	18.0	8.8	10.1	8.5
	医薬品	Pharmaceuticals	21.7	19.1	10.6	12.5	18.3
	その他	Others	13.7	9.0	17.7	19.1	26.7
	合計	Total	110.2	125.8	124.9	159.8	142.5
設備投資額の内訳 (十億円) Breakdown of capital expenditures (billions of yen)	新設・増強	New plants and expansions					
	基礎化学	Basic Chemicals	6.6	10.2	11.4	18.7	13.1
	石油化学	Petrochemicals & Plastics	3.6	5.7	4.2	4.3	1.3
	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	3.6	3.7	1.9	1.9	3.1
	情報電子化学	IT-related Chemicals	33.9	36.5	34.8	66.6	27.6
	健康・農業関連事業	Health & Crop Sciences	1.7	14.0	4.0	4.7	2.1
	医薬品	Pharmaceuticals	8.0	1.0	0.7	1.9	11.2
	その他	Others	1.1	1.4	3.0	5.5	3.2
	小計	Sub-total	58.4	72.3	60.0	103.6	61.6
	合理化	Rationalization of production processes	4.7	7.4	6.2	6.8	5.1
	研究開発	R&D	9.8	7.3	9.0	7.1	6.5
	更新・補修	Maintenance and renewal	14.5	14.0	17.5	22.6	37.8
	その他	Others	22.8	24.7	32.2	19.8	31.4
	合計	Total	110.2	125.8	124.9	159.8	142.5
減価償却費 (十億円) Depreciation and amortization expenses (billions of yen)	基礎化学	Basic Chemicals	11.3	10.8	11.8	13.5	13.2
	石油化学	Petrochemicals & Plastics	18.2	17.8	18.8	19.2	18.4
日本基準	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	6.8	6.3	6.7	6.5	6.1
	情報電子化学	IT-related Chemicals	10.5	18.4	24.9	31.5	42.2
	健康・農業関連事業	Health & Crop Sciences	11.9	12.0	15.2	14.2	12.8
	医薬品	Pharmaceuticals	12.2	10.5	14.2	16.2	15.4
	その他	Others	11.6	12.3	13.2	12.8	16.9
	合計	Total	82.5	88.2	104.9	113.9	125.0
研究開発費 (十億円) Research and development expenses (billions of yen)	基礎化学	Basic Chemicals	2.5	2.8	2.7	5.7	6.1
	石油化学	Petrochemicals & Plastics	7.8	7.6	7.4	11.3	11.1
日本基準	エネルギー・機能材料	Energy & Functional Materials	—	—	—	—	—
	精密化学	Fine Chemicals	3.3	3.3	3.1	4.2	4.1
	情報電子化学	IT-related Chemicals	6.4	8.1	10.6	12.6	13.7
	健康・農業関連事業	Health & Crop Sciences	15.3	16.0	16.5	18.7	19.4
	医薬品	Pharmaceuticals	27.7	27.4	35.8	42.5	47.8
	その他	Others	12.2	13.0	15.8	2.6	3.2
	合計	Total	75.2	78.2	91.9	97.7	105.4

\*1 2011年3月期から全社共通研究費の配賦方法等を見直している。また一部の連結子会社を「その他部門」からセグメントを変更している(2010年3月期は組替後を掲載)。

\*2 2012年3月期から「精密化学部門」を廃止・再編し、同セグメントの事業を「基礎化学部門」と「農業化学部門」に移管、また「農業化学部門」を「健康・農業関連事業部門」に改称(2011年3月期は組替後を掲載)。

\*3 2016年3月期から、従来の基礎化学部門および石油化学部門の事業を「石油化学事業」と「エネルギー・機能材料事業」に再編し、両事業部門を「石油化学部門」と「エネルギー・機能材料部門」に改組(2015年3月期は組替後を掲載)。

\*4 2017年3月期から、情報電子化学部門に含まれていた電池部材およびエンジニアリングプラスチックをエネルギー・機能材料部門に移管(2016年3月期は組替後を掲載)。

国際会計基準 (IFRS) (百万円 Millions of yen)

	'09/3	'10/3*1	'11/3*1,2	'12/3*2	'13/3	'14/3	'15/3*3	'16/3*3,4	'17/3*4	'18/3	'19/3	(監査中 Unaudited) '20/3	
¥ 240,030	¥ 203,294	¥ 302,289	¥ 284,348	¥ 263,522	¥ 286,898	¥ —	¥ —	¥ —	¥ —	¥ —	¥ —	¥ —	
552,974	481,529	649,885	672,428	693,859	792,021	932,294	657,093	202,844	209,007	206,414	250,988	282,850	656,929
80,763	86,713	—	—	—	—	—	—	—	—	—	—	—	255,034
307,121	265,226	322,287	293,066	299,968	362,255	405,126	384,532	358,473	368,709	396,839	404,871	404,871	404,871
222,202	211,546	250,806	264,134	262,580	326,967	345,383	359,013	320,613	339,698	338,094	343,666	343,666	343,666
235,590	267,464	410,614	380,518	378,595	418,809	403,562	435,478	440,974	500,227	492,130	515,845	515,845	515,845
149,543	105,143	46,554	53,390	53,968	56,844	87,488	56,641	54,743	56,771	51,130	49,459	49,459	49,459
1,788,223	1,620,915	1,982,435	1,947,884	1,952,492	2,243,794	2,376,697	2,101,764	1,939,069	2,190,509	2,318,572	2,225,804	2,225,804	2,225,804
(15,334)	1,328	20,627	9,349	(6,391)	(10,867)	—	—	—	—	—	—	—	—
(30,337)	(247)	11,130	6,155	(3,232)	4,942	20,809	28,767	58,884	94,567	61,610	14,485	14,485	14,485
—	—	—	—	—	—	783	2,809	6,030	19,189	22,959	20,343	20,343	20,343
1,629	3,579	—	—	—	—	—	—	—	—	—	—	—	—
(996)	6,304	26,138	10,968	11,703	34,898	32,408	19,874	8,714	12,341	26,227	25,084	25,084	25,084
24,429	29,264	23,302	26,495	26,272	38,184	56,117	77,518	47,440	43,964	19,716	2,083	2,083	2,083
32,350	29,889	28,654	20,918	30,857	47,079	29,024	42,686	69,871	94,786	80,764	75,266	75,266	75,266
(7,891)	6,714	4,128	7,720	7,963	8,373	15,653	7,830	10,146	11,052	9,422	8,770	8,770	8,770
(1,736)	(25,376)	(26,022)	(20,917)	(22,156)	(21,767)	(27,448)	(15,038)	(16,538)	(13,205)	(16,446)	(13,379)	(13,379)	(13,379)
2,114	51,455	87,957	60,688	45,016	100,842	127,346	164,446	184,547	262,694	204,252	132,652	132,652	132,652
(6.39)	0.65	6.82	3.29	(2.43)	(3.79)	—	—	—	—	—	—	—	—
(5.49)	(0.05)	1.71	0.92	(0.47)	0.62	2.23	4.38	10.56	14.03	8.13	2.20	2.20	2.20
—	—	—	—	—	—	0.39	1.34	2.92	7.65	8.12	7.98	7.98	7.98
2.02	4.13	—	—	—	—	—	—	—	—	—	—	—	—
(0.32)	2.38	8.11	3.74	3.90	9.63	8.00	5.17	2.43	3.35	6.61	6.20	6.20	6.20
10.99	13.83	9.29	10.03	10.01	11.68	16.25	21.59	14.80	12.94	5.83	0.61	0.61	0.61
13.73	11.17	6.98	5.50	8.15	11.24	7.19	9.80	15.84	18.95	16.41	14.59	14.59	14.59
(5.28)	6.39	8.87	14.46	14.76	14.73	17.89	13.82	18.53	19.47	18.43	17.73	17.73	17.73
0.12	3.17	4.44	3.12	2.31	4.49	5.36	7.82	9.52	11.99	8.81	5.96	5.96	5.96
14.7	12.4	16.6	24.5	33.0	22.7	—	—	—	—	—	—	—	—
17.6	14.4	13.7	19.6	14.1	17.0	19.7	20.7	30.6	17.4	31.5	23.8	23.8	23.8
—	—	—	—	—	—	5.8	20.6	21.9	22.5	24.3	21.4	21.4	21.4
7.7	17.8	—	—	—	—	—	—	—	—	—	—	—	—
50.6	11.5	27.7	66.9	18.7	51.5	17.5	26.7	33.5	24.5	33.6	21.6	21.6	21.6
11.3	23.2	15.6	19.3	25.1	17.5	16.3	15.5	24.2	56.3	39.9	19.7	19.7	19.7
12.7	7.8	10.5	11.3	14.6	28.7	16.5	13.9	14.9	21.2	16.9	17.0	17.0	17.0
19.6	16.3	14.6	13.5	10.6	6.1	8.3	6.3	11.1	16.8	17.6	12.9	12.9	12.9
134.1	103.2	98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	116.3	116.3	116.3
3.8	1.2	3.4	6.9	18.1	4.0	—	—	—	—	—	—	—	—
2.9	1.9	2.3	6.1	6.8	10.2	2.5	1.8	—	3.2	6.4	6.7	6.7	6.7
—	—	—	—	—	—	1.1	10.0	—	14.3	13.0	11.1	11.1	11.1
3.3	11.0	—	—	—	—	—	—	—	—	—	—	—	—
47.9	8.7	23.9	62.2	15.8	48.1	12.9	22.1	—	21.3	28.3	16.8	16.8	16.8
2.0	17.7	7.8	9.2	15.4	8.6	10.6	6.4	—	38.0	22.9	8.9	8.9	8.9
2.9	2.0	0.7	1.7	1.6	1.9	1.6	1.9	—	3.7	6.1	5.4	5.4	5.4
5.6	7.6	5.7	1.0	2.6	0.6	0.9	0.7	—	6.0	8.6	0.7	0.7	0.7
68.4	50.1	43.8	87.1	60.3	73.4	29.6	43.0	—	86.5	85.4	49.7	49.7	49.7
6.0	5.4	4.6	3.9	3.1	4.8	4.5	8.3	—	2.7	2.8	2.2	2.2	2.2
9.6	7.7	6.7	10.6	12.9	13.0	8.3	7.4	—	12.1	13.6	7.4	7.4	7.4
23.0	18.9	23.7	30.3	22.4	27.2	22.7	21.7	—	31.3	43.9	32.1	32.1	32.1
27.2	21.2	19.9	23.2	17.4	25.0	19.1	23.3	—	26.2	17.9	25.1	25.1	25.1
134.1	103.2	98.7	155.1	116.1	143.4	84.2	103.8	136.3	158.8	163.7	116.3	116.3	116.3
17.2	14.2	21.2	14.2	15.5	18.0	—	—	—	—	—	—	—	—
20.9	19.4	18.4	14.1	13.7	12.8	22.6	22.2	22.8	23.0	22.0	27.9	27.9	27.9
—	—	—	—	—	—	12.4	11.8	12.7	13.9	15.4	15.9	15.9	15.9
6.3	7.3	—	—	—	—	—	—	—	—	—	—	—	—
39.8	23.2	20.3	14.5	17.9	25.0	33.2	35.0	31.7	29.6	31.1	29.0	29.0	29.0
13.1	12.6	22.3	14.6	15.3	17.7	15.4	16.3	16.2	16.2	18.7	26.1	26.1	26.1
14.5	21.2	47.2	42.3	37.1	28.1	20.9	22.2	15.5	15.1	16.3	20.0	20.0	20.0
29.0	18.4	17.7	15.1	15.9	14.1	14.7	9.2	11.4	9.4	9.0	13.0	13.0	13.0
140.7	116.1	147.0	114.9	115.5	115.7	119.2	116.6	110.3	107.1	112.5	131.7	131.7	131.7
6.4	3.5	5.1	5.2	5.8	6.4	—	—	—	—	—	—	—	—
12.0	8.3	7.6	7.2	7.1	7.6	6.7	6.2	6.2	6.6	7.1	7.0	7.0	7.0
—	—	—	—	—	—	8.2	8.0	9.3	7.5	8.5	7.8	7.8	7.8
4.2	4.2	—	—	—	—	—	—	—	—	—	—	—	—
21.2	11.0	11.6	11.7	12.3	15.0	16.5	16.6	16.1	17.3	17.3	19.1	19.1	19.1
20.7	17.2	21.6	19.7	20.6	22.9	24.9	26.8	28.2	29.3	29.3	28.9	28.9	28.9
55.0	54.9	71.2	59.0	61.1	71.9	72.9	83.7	82.3	89.3	85.1	95.0	95.0	95.0
11.6	18.1	21.1	19.5	18.1	17.6	18.7	14.5	15.8	15.3	16.2	16.5	16.5	16.5
131.1	117.3	138.1	122.3	125.0	141.3	147.9	155.8	158.0	165.3	163.5	174.3	174.3	174.3

\*1 From FY2010, we have revised our method of allocation of R&D expenses for company-wide projects, etc. Certain consolidated subsidiaries, formerly categorized under the Others sector, have been re-categorized. (FY2009 figures have been recalculated using the revised method for purposes of comparison.)  
 \*2 As of FY2011, the Fine Chemicals Sector was eliminated and reorganized. The businesses in this sector were transferred to the Basic Chemicals Sector or the Agricultural Chemicals Sector. Following this change the Agricultural Chemicals Sector has changed its name to "Health & Crop Sciences" Sector. (The amounts for FY2010 have been reclassified by revised sectors.)  
 \*3 As of FY2015, the Basic Chemicals Sector was eliminated and businesses in this sector were split and transferred to the Petrochemicals & Plastics Sector and Energy & Functional Materials Sector that was established as a new business sector. In addition, a part of businesses in the Petrochemicals & Plastics Sector were transferred to the Energy & Functional Materials Sector. (The amounts for FY2014 have been reclassified by revised sectors.)  
 \*4 As of FY2016, battery materials and engineering plastics that had been included in the IT-related Chemicals Sector were transferred to the Energy & Functional Materials Sector. (The amounts for FY2015 have been reclassified by revised sectors.)